IEC On-Demand Webcasts
In effort to bring valuable information and education to a wider audience, the IEC continues to develop webcasts of the symposia taking place throughout the year. In each of these webcasts, leading experts in atopic dermatitis provide new insights and promote management through research, education, and patient/family care.
Please enjoy these complimentary webcasts. The IEC will announce new webcasts as they become available.
Atopic Dermatitis Involving the Face and Sensitive Areas
- Allergic contact/irritant dermatitis
- Epidemiology and Burden of Facial AD
- Treatment of atopic dermatitis involving the face
- Dupilumab-associated facial skin changes
- Mechanisms of Sensitive Skin
- Differences in diagnosis and treatment in the context of ethnic skin
Human Models of Atopic Dermatitis
- Human Equivalent Models
- Genetic variation in Human models
- Environmental Exposures and Allergens
- Human Models in vivo
- Computational Models of Atopic Dermatitis
- Panel Discussion
Management of Pediatric Atopic Dermatitis: A Global Perspective
- Welcome & History of ISPD and IEC
- Management of Pediatric AD: A Global Presepecitve
- Setting the scene for what’s new in therapy?
- Atopic Dermatitis in Skin of Color
- The Role of the Microbiome in Atopic Dermatitis
- Skin Infections in Atopic Dermatitis
- The Importance of Patient Education and Strategies for Delivery – A Global Perspective
- Panel Discussion
Biomarkers
- Cytokines and chemokines as a possible biomarker in atopic dermatitis
- Atopic Dermatitis 3.0: from clinical phenotypes to biomarker based endophenotypes
- Treatment response biomarkers and minimally invasive skin biomarkers
- Fireside Chat Panel Discussion
Hand Eczema
- Chronic Hand Eczema: Epidemiology, Etiology and Classification
- How to Run a Hand Eczema Clinic
- Hand Eczema - Contact Dermatitis
- Tools to Measure Hand Eczema Severity
- Current Therapeutic Strategies, Phototherapy, and Systemic Therapy
- New Topical and Systemic Treatments for Chronic Hand Eczema
Novel Systemic Treatments for Atopic Dermatitis and Clinical Trial Design
- Optimizing Clinical Trial Design for AD drug development
- Novel Systemic Treatments in Pediatrics and Placebo Responses in Systemic Trials
- Monoclonal antibodies targeting Th2 receptors and cytokines (e.g. IL4R, IL-13 and IL-31)
- Monoclonal antibodies targeting epithelial-derived protein (e.g. IL-17C, IL-33 and TSLP)
- Monoclonal antibodies with other targets (e.g. OX40, IL-22 and IL-23) and biomarkers of disease response
- Systemic JAK inhibitors
- Topical JAK inhibitors
New Treatments for Atopic Dermatitis in Infants and Children
- Overview of Pediatric AD
- Mechanisms for Prevention of AD
- Topical Therapies
- Systemic Therapies
Management of AD Patients on Systemic Treatments during COVID-19
- COVID-19 and Pediatric AD Patients
- COVID-19 and Adult AD Patients
- COVID-19 New York Patients Atopic Dermatitis Topical Study Design
- SECURE-AD Registry
New Topical Developments and Preventive Mechanisms
- Atopic Dermatitis Topical Study Design
- Mechanisms for Prevention of AD
- PDE-4 Inhibitors
- Topical Therapies: Tapinarof and Beyond
Atopic Dermatitis Comorbidities
- Atopic Comorbidities (e.g., asthma, hay fever, food allergy)
- Cardiovascular Comorbidities (e.g., diabetes and CVD)
- Autoimmune Comorbidities (e.g., vitiligo, urticaria, AA, RA)
- Cutaneous Comorbidities (e.g., contact allergy, irritant contact dermatitis, occupational hand eczema, infections, skin cancer)
- Psychiatric Comorbidities (e.g., anxiety, depression, sleep disorders, ADHD)
- Economics and Healthcare in Atopic Dermatitis
|
